Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
4.030
-0.080 (-1.95%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Oramed Pharmaceuticals Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Oramed Pharmaceuticals.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Oramed Pharmaceuticals.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 1 | 1 | 1 | 1 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Sep 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 20, 2024 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | -50.37% | May 17, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 17, 2023 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 12, 2023 |
Financial Forecast
Revenue This Year
n/a
from 2.00M
Revenue Next Year
n/a
EPS This Year
n/a
from 1.50
EPS Next Year
n/a
Revenue Forecast
| Revenue |
|---|
| High |
| Avg |
| Low |
Revenue Growth
| Revenue Growth |
|---|
| High |
| Avg |
| Low |
EPS Forecast
| EPS |
|---|
| High |
| Avg |
| Low |
EPS Growth
| EPS Growth |
|---|
| High |
| Avg |
| Low |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.